Skip to main content
Erschienen in: International Journal of Hematology 3/2017

15.11.2016 | Original Article

Iron overload patients with unknown etiology from national survey in Japan

verfasst von: Katsuya Ikuta, Mayumi Hatayama, Lynda Addo, Yasumichi Toki, Katsunori Sasaki, Yasuaki Tatsumi, Ai Hattori, Ayako Kato, Koichi Kato, Hisao Hayashi, Takahiro Suzuki, Masayoshi Kobune, Miyuki Tsutsui, Akihiko Gotoh, Yasuo Aota, Motoo Matsuura, Yuzuru Hamada, Takahiro Tokuda, Norio Komatsu, Yutaka Kohgo

Erschienen in: International Journal of Hematology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Transfusion is believed to be the main cause of iron overload in Japan. A nationwide survey on post-transfusional iron overload subsequently led to the establishment of guidelines for iron chelation therapy in this country. To date, however, detailed clinical information on the entire iron overload population in Japan has not been fully investigated. In the present study, we obtained and studied detailed clinical information on the iron overload patient population in Japan. Of 1109 iron overload cases, 93.1% were considered to have occurred post-transfusion. There were, however, 76 cases of iron overload of unknown origin, which suggest that many clinicians in Japan may encounter some difficulty in correctly diagnosing and treating iron overload. Further clinical data were obtained for 32 cases of iron overload of unknown origin; median of serum ferritin was 1860.5 ng/mL. As occurs in post-transfusional iron overload, liver dysfunction was found to be as high as 95.7% when serum ferritin levels exceeded 1000 ng/mL in these patients. Gene mutation analysis of the iron metabolism-related genes in 27 cases of iron overload with unknown etiology revealed mutations in the gene coding hemojuvelin, transferrin receptor 2, and ferroportin; this indicates that although rare, hereditary hemochromatosis does occur in Japan.
Literatur
1.
Zurück zum Zitat Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142:24–38.CrossRefPubMed Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142:24–38.CrossRefPubMed
4.
Zurück zum Zitat Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393–408.CrossRefPubMed Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393–408.CrossRefPubMed
5.
Zurück zum Zitat Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–10.CrossRefPubMed Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–10.CrossRefPubMed
7.
Zurück zum Zitat Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.CrossRefPubMed Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.CrossRefPubMed
8.
Zurück zum Zitat Siddique A, Kowdley KV. The iron overload syndromes. Aliment Pharmacol Ther. 2012;35:876–93.CrossRefPubMed Siddique A, Kowdley KV. The iron overload syndromes. Aliment Pharmacol Ther. 2012;35:876–93.CrossRefPubMed
9.
Zurück zum Zitat Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487–94.CrossRefPubMed Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487–94.CrossRefPubMed
10.
Zurück zum Zitat Hattori A, Miyajima H, Tomosugi N, et al. Clinicopathological study of Japanese patients with genetic iron overload syndromes. Pathol Int. 2012;62:612–8.CrossRefPubMed Hattori A, Miyajima H, Tomosugi N, et al. Clinicopathological study of Japanese patients with genetic iron overload syndromes. Pathol Int. 2012;62:612–8.CrossRefPubMed
11.
Zurück zum Zitat Hattori A, Tomosugi N, Tatsumi Y, et al. Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecules in a Japanese male patient with juvenile hemochromatosis. Blood Cells Mol Dis. 2012;48:179–82.CrossRefPubMed Hattori A, Tomosugi N, Tatsumi Y, et al. Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecules in a Japanese male patient with juvenile hemochromatosis. Blood Cells Mol Dis. 2012;48:179–82.CrossRefPubMed
12.
Zurück zum Zitat Hayashi H, Wakusawa S, Motonishi S, et al. Genetic background of primary iron overload syndromes in Japan. Intern Med. 2006;45:1107–11.CrossRefPubMed Hayashi H, Wakusawa S, Motonishi S, et al. Genetic background of primary iron overload syndromes in Japan. Intern Med. 2006;45:1107–11.CrossRefPubMed
13.
Zurück zum Zitat Koyama C, Wakusawa S, Hayashi H, et al. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica. 2005;90:302–7.PubMed Koyama C, Wakusawa S, Hayashi H, et al. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica. 2005;90:302–7.PubMed
14.
Zurück zum Zitat Koyama C, Wakusawa S, Hayashi H, et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med. 2005;44:990–3.CrossRefPubMed Koyama C, Wakusawa S, Hayashi H, et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med. 2005;44:990–3.CrossRefPubMed
15.
Zurück zum Zitat Koyama C, Hayashi H, Wakusawa S, et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol. 2005;43:740–2.CrossRefPubMed Koyama C, Hayashi H, Wakusawa S, et al. Three patients with middle-age-onset hemochromatosis caused by novel mutations in the hemojuvelin gene. J Hepatol. 2005;43:740–2.CrossRefPubMed
16.
Zurück zum Zitat Nagayoshi Y, Nakayama M, Suzuki S, et al. A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur J Heart Fail. 2008;10:1001–6.CrossRefPubMed Nagayoshi Y, Nakayama M, Suzuki S, et al. A Q312X mutation in the hemojuvelin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur J Heart Fail. 2008;10:1001–6.CrossRefPubMed
17.
Zurück zum Zitat Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77–82.CrossRefPubMed Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77–82.CrossRefPubMed
18.
Zurück zum Zitat Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105:1803–6.CrossRefPubMed Nemeth E, Roetto A, Garozzo G, et al. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105:1803–6.CrossRefPubMed
19.
Zurück zum Zitat Li S, Xue J, Chen B, et al. Two middle-age-onset hemochromatosis patients with heterozygous mutations in the hemojuvelin gene in a Chinese family. Int J Hematol. 2014;99:487–92.CrossRefPubMed Li S, Xue J, Chen B, et al. Two middle-age-onset hemochromatosis patients with heterozygous mutations in the hemojuvelin gene in a Chinese family. Int J Hematol. 2014;99:487–92.CrossRefPubMed
20.
Zurück zum Zitat Biasiotto G, Camaschella C, Forni GL, Polotti A, Zecchina G, Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica. 2008;93:309–10.CrossRefPubMed Biasiotto G, Camaschella C, Forni GL, Polotti A, Zecchina G, Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica. 2008;93:309–10.CrossRefPubMed
21.
Zurück zum Zitat Santos PC, Cançado RD, Pereira AC, et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis. 2011;46:302–7.CrossRefPubMed Santos PC, Cançado RD, Pereira AC, et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis. 2011;46:302–7.CrossRefPubMed
22.
Zurück zum Zitat Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood. 2002;100:692–4.CrossRefPubMed Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood. 2002;100:692–4.CrossRefPubMed
23.
Zurück zum Zitat Zoller H, McFarlane I, Theurl I, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology. 2005;42:466–72.CrossRefPubMed Zoller H, McFarlane I, Theurl I, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology. 2005;42:466–72.CrossRefPubMed
24.
Zurück zum Zitat Schimanski LM, Drakesmith H, Merryweather-Clarke AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood. 2005;105:4096–102.CrossRefPubMed Schimanski LM, Drakesmith H, Merryweather-Clarke AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood. 2005;105:4096–102.CrossRefPubMed
25.
Zurück zum Zitat Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408.CrossRefPubMed Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408.CrossRefPubMed
26.
27.
Zurück zum Zitat Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet. 2001;69:191–7.CrossRefPubMedPubMedCentral Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet. 2001;69:191–7.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Mims MP, Guan Y, Pospisilova D, et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood. 2005;105:1337–42.CrossRefPubMed Mims MP, Guan Y, Pospisilova D, et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood. 2005;105:1337–42.CrossRefPubMed
Metadaten
Titel
Iron overload patients with unknown etiology from national survey in Japan
verfasst von
Katsuya Ikuta
Mayumi Hatayama
Lynda Addo
Yasumichi Toki
Katsunori Sasaki
Yasuaki Tatsumi
Ai Hattori
Ayako Kato
Koichi Kato
Hisao Hayashi
Takahiro Suzuki
Masayoshi Kobune
Miyuki Tsutsui
Akihiko Gotoh
Yasuo Aota
Motoo Matsuura
Yuzuru Hamada
Takahiro Tokuda
Norio Komatsu
Yutaka Kohgo
Publikationsdatum
15.11.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2141-9

Weitere Artikel der Ausgabe 3/2017

International Journal of Hematology 3/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.